Q2 EPS Forecast for Monopar Therapeutics Raised by Analyst

Monopar Therapeutics Inc. (NASDAQ:MNPR) – Stock analysts at HC Wainwright upped their Q2 2026 earnings estimates for Monopar Therapeutics in a report issued on Friday, May 15th. HC Wainwright analyst A. Maldonado now anticipates that the company will post earnings per share of ($0.68) for the quarter, up from their prior forecast of ($0.82). The consensus estimate for Monopar Therapeutics’ current full-year earnings is ($4.11) per share. HC Wainwright also issued estimates for Monopar Therapeutics’ Q3 2026 earnings at ($0.79) EPS, Q4 2026 earnings at ($0.95) EPS, FY2026 earnings at ($2.90) EPS, FY2027 earnings at ($1.37) EPS, FY2028 earnings at $0.52 EPS and FY2030 earnings at $5.50 EPS.

Monopar Therapeutics (NASDAQ:MNPR) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.41.

Several other research analysts have also recently weighed in on the stock. BTIG Research restated a “buy” rating and set a $104.00 price target on shares of Monopar Therapeutics in a report on Monday, February 23rd. Chardan Capital reaffirmed a “buy” rating and issued a $100.00 price objective on shares of Monopar Therapeutics in a research report on Monday, March 30th. Wall Street Zen raised shares of Monopar Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Monopar Therapeutics in a research report on Tuesday, April 21st. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Monopar Therapeutics in a research report on Wednesday, January 21st. Two analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Monopar Therapeutics presently has a consensus rating of “Buy” and an average target price of $107.00.

Monopar Therapeutics Price Performance

Shares of NASDAQ MNPR opened at $56.25 on Tuesday. The stock has a market capitalization of $376.88 million, a P/E ratio of -29.61 and a beta of 1.49. The company has a 50-day moving average price of $56.97 and a 200-day moving average price of $65.54. Monopar Therapeutics has a 1 year low of $28.40 and a 1 year high of $105.00.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MNPR. Wellington Management Group LLP purchased a new position in Monopar Therapeutics in the third quarter valued at about $18,904,000. Siren L.L.C. purchased a new position in Monopar Therapeutics in the fourth quarter valued at about $13,863,000. Deerfield Management Company L.P. purchased a new position in Monopar Therapeutics in the third quarter valued at about $13,048,000. RA Capital Management L.P. boosted its stake in Monopar Therapeutics by 30.5% in the fourth quarter. RA Capital Management L.P. now owns 667,207 shares of the company’s stock valued at $43,569,000 after acquiring an additional 156,000 shares during the last quarter. Finally, TCG Crossover Management LLC purchased a new position in Monopar Therapeutics in the third quarter valued at about $12,496,000. 1.83% of the stock is currently owned by hedge funds and other institutional investors.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.